Drug policy & crime

Would legalising drugs reduce harm?

The short answer

Sometimes. Outcomes depend on the drug, the rules and available support. Legal does not mean less harmful.

Fewer possession charges do not prove less violence or organised crime. What works for cannabis may not work for other drugs.

Sources checked: · 26 source entries

AI-assisted research and writing. Not independently reviewed by a subject-matter expert. About & methodology.

The evidence in one minute

Legal does not mean less harmful. Alcohol can cause more overall harm than some prohibited drugs. That challenges existing rules, but does not prove that every form of legalisation works better.

Ask two questions: how harmful is the substance, and which policy causes least overall harm? A harmful substance can rationally remain legal if prohibition would be worse.

  • Compare like with like. Smoking is not the same as medicinal nicotine. Overall harm scores do not tell you the risk per dose.
  • Possession is not selling. Portugal did not legalise drug sales. Canada shows more legal cannabis purchasing and fewer possession charges—not the same fall in all crime.
  • US prohibition had mixed effects. Consumption fell, while illegal trade flourished. Repeal did not eliminate organised crime.
  • Rules matter. Pricing, marketing, treatment and enforcement affect outcomes. Crime can decline, persist or shift; no blanket reduction percentage is defensible.

Research date: 20 September 2026. AI-assisted research and writing; no independent clinical or criminological review. General information, not personal advice. Sources cover different observation periods, not necessarily the situation today.

3 minutes

Understand the essentials in three minutes

Three common claims, what the evidence supports, and why the distinction matters.

Legal drugs are less harmful than illegal ones.

Not a defensible general rule

Alcohol ranked highest for combined harm to users and others in a British expert assessment. That challenges a simple division into safer legal drugs and more harmful illegal drugs. But the ranking combines different harms and judgement calls: it is not a risk per dose. It also cannot tell us which policy would cause the least harm.[2][3][4]

Explore the evidence →

Portugal shows what happens when all drugs are sold legally.

That is not what changed

Portugal moved personal possession within its rules away from criminal punishment, but did not legalise production or drug sales. Treatment and other support changed alongside the law. Encouraging health trends therefore cannot all be attributed to decriminalisation alone. The policy analysis discussed here also describes continuing problems and historical developments, not a complete account of the current legal position.[5]

Explore the evidence →

Fewer drug charges mean less crime overall.

Different outcomes are being confused

Canada recorded far fewer cannabis possession charges after legalisation. Avoiding prosecution can genuinely benefit people, but a fall in charges for conduct that is no longer an offence does not measure violence or organised crime. More purchasing from legal suppliers is another separate outcome. The Canadian review describes a continuing illegal market and health concerns alongside these changes.[7]

Explore the evidence →

Ask what changes, and what is measured

Separate possession, production and sales. Then ask which substance, which rules and which outcome a claim concerns. Compare health, victims and enforcement, not just the size of the legal market. No single crime-reduction percentage answers all those questions.

Explore the evidence →
Full research & sources25 min reading time, approximately

Study details, limitations, counterarguments and original sources. Open to read; all content is also available when printing.

Context: the violent incident in Overasselt on 1 September 2026 prompted this report. Police reported 1 death and 2 injured officers.[19] This report examines drug policy, not who did what in that ongoing case. A violent incident alone cannot prove that legalisation would prevent it, or that prohibition is preferable.

1. “Legalisation” is not a single policy

Public debate often contrasts “banning drugs” with “allowing drugs”. Actual policy has several separate components: possession, production, distribution, retailing, advertising and treatment. A country can relax one component while retaining strict controls on another. These distinctions determine which benefits and risks are plausible. They also prevent a successful treatment trial being presented as evidence for unrestricted retail sales.[1]

Different changes, different mechanisms
ModelWhat changes?What does not automatically follow?
Possession decriminalisationPersonal possession is removed from criminal law within the applicable rules; administrative responses may remain.Production and sale do not become legal. An illegal supply chain can remain intact.
DepenalisationPenalties are reduced or not applied in practice, while conduct may remain a criminal offence.There is not necessarily a legal right to possess or sell.
Tolerated saleAuthorities do not prosecute retail sales that meet specified conditions.The supplier to that retailer need not be operating legally.
Regulated production and saleAuthorised suppliers may produce and sell within a legal framework.This need not involve advertising, unrestricted availability or profit-driven expansion.
CommercialisationBusinesses compete for customers and revenue, within whatever restrictions apply.Commercial success is not the same as better population health.
Prescription or heroin-assisted treatmentSelected patients receive a pharmaceutical product under medical supervision.This is not general access for recreational consumers.

Terminology varies between publications. Therefore, look beyond the label: who can obtain which product, from whom, and with what oversight? A public monopoly, a non-profit model and competitive commercial retailers can all be described as regulated legal supply, yet create different incentives. Age restrictions, product standards and marketing rules are substantive policy choices, not minor details.

Heroin-assisted treatment illustrates the importance of this distinction. A Cochrane review of 8 randomised studies involving 2,007 participants found benefits for treatment retention and reduced illicit drug use among people with longstanding dependence and previous treatment failures. Some studies also found less offending. Medication-related adverse events were more frequent; the mortality result was uncertain. The evidence supports a carefully supervised option for a selected clinical group, not the safety of an open heroin market.[10]

2. Alcohol, nicotine, MDMA and cocaine: what is the fair comparison?

Legal does not mean less harmful. It is not scientifically defensible to claim that alcohol and tobacco are permitted because they are safer than every prohibited drug. Equally, an illegal drug's lower score on a particular harm measure does not make it harmless or settle how it should be regulated.

Alcohol and nicotine are psychoactive substances. Their legal status does not put them outside the health discussion. WHO attributes about 2.6 million deaths worldwide in 2019 to alcohol. Tobacco causes millions of deaths annually, including deaths from second-hand smoke. These are population burdens, not the probability that a particular occasion of drinking or smoking will be fatal.[2][3]

A fair comparison specifies the outcome: acute poisoning, dependence, cancer, cardiovascular disease, psychosis, injury or harm to other people. It also specifies exposure: amount, frequency, duration, route of administration, product composition and combinations with other substances. Comparing occasional use of one drug with prolonged heavy use of another does not establish a general safety ranking.

Individual risk and population burden are different. A widely used substance can cause substantial total harm even when the risk per exposure is lower on a particular measure. A less common substance can have a high risk for its users while accounting for fewer deaths nationally. Neither “more deaths overall” nor “fewer deaths overall” is a sufficient answer to whether a particular product or policy is safer.

Tobacco's major disease burden is strongly connected to its products and patterns of exposure, including smoke; nicotine dependence and smoke-related disease are not interchangeable concepts. Alcohol contributes to cancer, liver disease, injuries and violence. These examples support taking regulation seriously, rather than treating existing legal markets as an ideal template. WHO documents benefits from tobacco taxation and advertising restrictions, while illicit tobacco trade still exists.[2][3]

Compare the actual products, not just “legal” and “illegal”

Established concerns and the limits of the comparison—not equal-dose risk estimates
Substance or productImportant harmsWhat a fair comparison must distinguish
AlcoholDependence, cancer and liver disease, as well as poisoning, injuries and violence.[2]Long-term disease and harm to others matter alongside immediate toxicity. Its large population burden is not a risk estimate for a single drink.
Smoked tobaccoNicotine dependence and major cancer, cardiovascular and lung-disease burdens; second-hand smoke harms others.[3]A low likelihood of immediate fatal poisoning does not make repeated smoking low-risk. Much of its disease burden develops over time.
Nicotine without tobacco smokeNicotine is highly addictive. Approved medicinal patches and gum avoid the toxic mixture in cigarette smoke and are far less harmful than smoking.[20]Do not assign cigarette cancer risks to nicotine itself. Vapes and other nicotine products are not equivalent to medicinal nicotine, and absence of combustion does not mean absence of risk.
MDMA / ecstasySerious acute complications can include overheating, dangerously low blood sodium and heart or liver problems; some are fatal. Longer-term cognitive effects remain an area of concern and uncertainty.[17][21]Dose, individual susceptibility, other substances and setting affect risk. Unknown contents add risks, but purity control would not remove MDMA's own toxicity.
Cocaine, including crackStrong reinforcement and dependence, raised heart rate and blood pressure, and potentially fatal toxicity. Dependence can be particularly pronounced with smoked cocaine.[22]Powder and crack are forms of the same drug, but route and speed of delivery matter. Their patterns of use should not be treated as interchangeable.

This table identifies relevant harms; it does not estimate how often each occurs under comparable conditions. There is no universal conversion between a drink, a cigarette and an episode of MDMA or cocaine use. A valid numerical comparison needs a specified outcome, exposure and population—not just a count of deaths or a legal label.

What about the famous drug-harm rankings?

Nutt and colleagues' British analysis, published in 2010, scored 20 substances against 16 criteria. Alcohol ranked highest for combined harm to users and others, with a score of 72, compared with 55 for heroin and 54 for crack cocaine. Crack cocaine, heroin and methamphetamine had the highest scores for harm to users themselves. These are weighted scores, not percentages or risks per dose. This was a structured expert assessment, not an experiment giving comparable exposures to participants.[4]

Such an exercise makes overlooked harms visible. But the overall score depends on judgements about how much weight to give dependence, death, family disruption, economic costs and other outcomes. It also reflects the social setting and existing markets. The result is not an objective, universal league table and does not show that a lower-ranked drug is harmless. Nor does it directly predict what would happen if that drug became more available.

Is the different legal treatment logically supported by evidence?

Not simply by saying “the prohibited drugs are more harmful”. Nutt and colleagues found poor correspondence between their harm scores and UK drug classification. Their analysis challenges a harm-only explanation of those classifications; it is not a complete assessment of current Dutch law. The evidence does not justify treating legality as a certificate of relative safety.[4]

But two different judgements are involved: how harmful use is, and whether prohibition does less harm than a specified alternative. A harmful substance can rationally remain legal if a ban would have worse consequences. That does not automatically justify prohibiting a different substance, nor prove that it should be sold in an unrestricted commercial market. The comparison must include the costs of keeping the existing rules, not only the risks of changing them.

  • Separate the substance from the market. Dependence and toxicity do not disappear with legal supply. Uncertain composition, criminal disputes and punishment can add harms under prohibition.
  • Compare realistic alternatives. Supervised medical access, possession decriminalisation, restricted regulated supply and commercial retail are different choices. Ask how each affects use, health, victims and enforcement.
  • Apply the same standards. Existing legality should not exempt alcohol or tobacco from scrutiny. Existing illegality should not count as evidence that prohibition works.

For example, legal nicotine medicines for smoking cessation have a product-specific health rationale; that is not a defence of cigarette sales on the same grounds. Likewise, evidence that MDMA or cocaine can cause serious harm is a reason to take risks seriously, but not by itself proof that criminal punishment of users is the most effective response.

Bottom line: a consistent policy needs a substance-specific justification for its rules and an assessment of their net consequences. History and social acceptance help explain existing arrangements; they do not establish their scientific merit. Evidence informs the choice, while the weight given to freedom, protection and fairness remains a value judgement.

3. What can the research actually establish?

Policy research rarely has the experimental control of a clinical trial. Countries choose reforms rather than being randomly assigned to them. Treatment provision, policing, the economy and retail rules often change at the same time. A before-and-after graph can reveal a trend, but not necessarily the cause. The hardest question is: what would have happened in the same place without the reform? We cannot directly observe that situation.

Comparison regions, interrupted time-series analyses and synthetic controls can improve causal inference. They still depend on assumptions: comparable underlying trends, no major unmeasured simultaneous change, and limited spillovers across borders. Researchers can reach different estimates by selecting different comparison areas, start dates or outcomes. A null result may mean little effect, but also insufficient data to detect one.

A systematic review by Scheim and colleagues, published in 2020 and searching studies through October 2018, included 114 articles. Of these, 109 concerned cannabis and 104 came from the United States. Many designs were relatively weak, and outcomes focused heavily on use rather than wider health and social effects. Its finding that many measures showed no change is not proof that every reform is harmless or ineffective.[1]

The evidence is therefore strongest for some narrower questions, such as changes in cannabis possession enforcement, purchasing patterns and selected treatment outcomes. It is much thinner for the net effect of legal retail cocaine or MDMA, or for nationwide changes in organised-crime violence. Cannabis is not a reliable substitute for studying drugs with different dependence patterns, acute toxicity, markets and consumer populations.

4. Portugal: decriminalisation, not legal drug shops

Portugal's reform took effect in 2001. Possession for personal use within its framework moved from criminal punishment to an administrative system, involving commissions that can assess the situation and direct people towards support. Unauthorised drug production and trafficking did not become lawful. “Portugal legalised all drugs” is therefore a misleading description.[5]

The reform belonged to a broader response involving treatment and harm reduction. Published assessments describe encouraging trends, including reductions in infectious disease and some criminal-justice burdens. They do not establish that the legal change alone caused all improvements. The epidemic was changing, services were changing, and different indicators cover different populations and periods.

A critical policy analysis published in 2021 also describes limitations: continuing stigma, uneven development of harm reduction and legal interpretations that complicated the simple story of “no criminal punishment”. That article analyses historical developments, not the complete legal position in 2026. It is useful precisely because it does not treat Portugal as an uncomplicated success story.[5]

The defensible lesson is that treating personal drug use primarily as a health and social issue can coexist with criminal enforcement against suppliers. It does not establish an optimal retail model or a guaranteed reduction in overdose deaths. Decriminalisation without accessible treatment, housing and other support should not be assumed to reproduce a broader policy package; equally, problems in service delivery do not by themselves prove that criminalising possession would improve health.

5. Canada: an important distinction between market share and harm

Canada legalised non-medical cannabis in 2018, with regulated production and sales. Its experience offers evidence about a legal cannabis market, not about legal retail sales of all drugs. Federal rules and provincial differences also mean that “the Canadian model” contains more than one retail arrangement.[7]

Official data show substantial substitution towards legal suppliers. However, several commonly quoted percentages measure different things. Spending, usual source, any legal purchase and exclusive legal purchasing are not interchangeable. Survey respondents may also misunderstand whether a seller is licensed.

Verified Canadian figures and their limits
Measure and periodFindingDo not interpret this as…
Estimated household spending on non-medical cannabis, third quarter of 2023 73% was spent with legal suppliers, according to the Statistics Canada estimate quoted in the expert review.[7]A share of all drugs, all physical cannabis consumed or all criminal income.
Usual source among past-year cannabis consumers, 2024 survey 72% reported legal shops or websites, compared with 37% in 2019.[6]Proof that these respondents obtained every product legally, or that the remainder all bought from criminals.
Past-year non-medical use among people aged 16 and older, 2024 survey 26%, compared with 22% in 2018.[6]A causal estimate of the effect of legalisation, or the percentage with dependence.

The expert panel's 2024 report welcomed movement into the regulated market and fewer possession charges, while describing a persistent illicit market. It also highlighted high-potency products, accidental poisonings among children and increased cannabis-related health-care presentations. These concerns cannot be dismissed merely because legal purchasing increased.[7]

What about young people and overall health?

The panel described youth use as relatively stable after legalisation, but still high, and use among young adults as increasing. “Youth”, “young adults” and “all adults” are different groups. Stable prevalence also does not rule out changes in frequency, product strength or problems among a smaller group of frequent users. The cannabis survey itself warns that its recruitment methods may produce higher prevalence estimates than other Canadian surveys.[6][7]

Canada thus demonstrates both opportunities and constraints: meaningful legal-market substitution, continued illegal supply and unresolved health concerns. It does not provide a single “success percentage”. A programme can reduce criminal-justice harm while failing to reduce some medical harms, and both findings deserve to be reported.

6. The United States: mixed findings need not be contradictory

US states introduced different medical and recreational laws at different times. Permission to possess, the opening of retailers and later market expansion are separate events. A study of medical access is not automatically a study of commercial recreational supply. National averages can also conceal local effects.

Lu and colleagues' study, published in 2019, used comparison states and interrupted time-series methods to examine the early legalisation and retail-sales periods in Colorado and Washington. It found no statistically significant long-term effect on aggregate violent or property crime in those states. That argues against confident claims of either a general crime explosion or a large general crime reduction in that setting.[8]

A different study by Wu and Willits, published in 2022, used data from 2007–2017 and found an increase in recorded simple assault in Oregon counties relative to comparison states after recreational legalisation. It concerned a different outcome and setting, not the same test with the opposite answer. Neither study measures every form of victimisation or proves that cannabis caused a particular violent act.[9]

Health and safety findings are similarly outcome-specific. A 2024 systematic review of traffic-injury emergency visits and hospitalisations included 7 studies from Canada and the United States: 4 reported increases after legalisation and 3 found no significant change. The authors identified moderate overall risk of bias and could not pool results because studies differed. This is reason for careful monitoring, not a universal numerical prediction for Dutch roads.[18]

7. Why a falling crime count is not the whole answer

If conduct ceases to be an offence, recorded offences for that conduct can fall without any change in how often people do it. Canada's expert panel reports a 95% reduction in cannabis possession charges between 2017 and 2022. This is an important reduction in exposure to criminal proceedings, but it is not a 95% reduction in violence, drug use or organised crime.[7]

Calling this only a “statistical trick” is also unfair. Avoiding prosecution, a conviction and related disruption can be a real benefit. The point is to name the outcome accurately. The legal definition changes the count; the reduction in criminal-justice involvement can still matter to people.

What should be measured separately?
IndicatorWhat it helps answerMain limitation
Drug arrests and chargesHow much criminal-justice intervention occurs?Depends directly on the law and enforcement priorities.
Total police-recorded crimeHow many offences reach police records?Depends on reporting, recording practices and the mix of offences.
Victimisation surveysHow many people report experiencing specified crimes, including unreported ones?Recall, non-response and exclusions matter; hidden organised crime is poorly covered.
Homicide, injury and emergency-care dataAre serious harms changing?Drug-market attribution is difficult; medical coding and care-seeking can change.
Illegal-market revenue and violenceIs the business model of organised crime weakening?Hidden revenues, overlapping activities and uncertain market-size estimates.

The Dutch CBS Safety Monitor illustrates a different way of measuring crime: 20% of residents aged 15 and older reported experiencing traditional crime in 2023, compared with 17% in 2021. This is a survey measure of victimisation, not a police-recorded crime total, and not an evaluation of drug legalisation. “Traditional crime” here covers violence, property crime and vandalism; online crime is reported separately.[11]

Seizures and dismantled laboratories need similar caution. More discoveries may indicate a larger market, better detection or a changed investigative focus. Fewer discoveries may indicate either less activity or less detection. The Dutch National Drug Monitor explicitly describes fragmented seizure data and incomplete coverage. Counting discoveries alone cannot settle whether a drug policy succeeded.[15]

8. Violence has more than one connection to drugs

Intoxication-related violence concerns effects of a substance, interactions with other substances and the surrounding circumstances. Alcohol is an important example. Individual history, provocation and setting also matter. The Dutch National Drug Monitor stresses these contextual factors; toxicology among selected suspects is not a representative sample of every violent incident or proof of causation.[16]

Acquisitive offending concerns obtaining money to sustain costly use or dependence. Effective treatment and social support may reduce that pressure for some people. Findings from supervised heroin treatment are relevant here, but not evidence that all crime by people who use drugs is caused by the price of drugs. Housing insecurity, other dependencies and pre-existing offending can remain.[10]

Market violence concerns disputes over territory, debts, retaliation and control of illegal business. Regulated suppliers can in principle use contracts and courts rather than private coercion. Moving transactions out of illegal markets could therefore reduce one source of violence. But violence can persist in residual illegal markets, around other substances or in unrelated disputes. Legal status does not remove every motive for intimidation or robbery.

A 2011 systematic review by Werb and colleagues found that most included studies associated intensified drug-law enforcement with more market violence. Disruption may create unstable competition, but the predominantly observational evidence does not show that every police intervention causes violence, or that every legalisation model prevents it. Targeting violence and corruption differs from indiscriminate market disruption. The mechanism matters more than the slogan “more policing” or “less policing”.[12]

9. Displacement: neither automatically complete nor absent

“Criminals will simply do something else” identifies a real possibility, not a measured law of nature. People, networks and assets can move into other illegal activities. But another market must offer customers, opportunities and workable margins; competition and barriers to entry do not disappear. Losing a profitable market can therefore reduce criminal income even if some participants adapt.

Separate market substitution from crime displacement. A consumer switching to a licensed cannabis shop is the former. A former supplier moving into extortion or another drug market is the latter. A legal share can rise while the illegal market's absolute size stays stable if total demand expands. Revenue can also fall through lower prices without a proportionate reduction in physical volume.

Residual illegal supply is especially plausible where legal prices are unattractive, authorised shops are inaccessible or consumers seek excluded products. Taxes and compliance costs can affect the price gap. Age limits deliberately leave minors outside legal retail access. Yet lowering taxes or expanding availability to compete with illicit sellers can conflict with health protection. Canada's expert panel describes both displacement of illegal trade and continuing illicit operators; neither a completely eliminated market nor no displacement fits that account.[7]

To measure net displacement, researchers need to follow people, markets, revenues, violence and neighbouring areas over time. Counting a new offence elsewhere is insufficient: it may have increased anyway. Assuming complete replacement overstates offenders' flexibility; assuming none ignores it. For Dutch policy, the honest answer is that the proportion is uncertain and likely varies by substance, network, geography and timeframe.

10. What is realistically at stake in the Netherlands?

The Netherlands did not historically legalise the entire cannabis supply chain. Coffeeshop retail sales are tolerated under conditions, while supply outside authorised arrangements remains illegal. That is the familiar backdoor problem: tolerated retailing coupled to unlawful wholesale production and supply. Describing the whole system as legal obscures the very problem that supply-chain reform seeks to address.[13]

The controlled cannabis supply-chain experiment is a specific exception, not general legalisation of drugs. The government's timeline records the experimental phase beginning on 7 April 2025, with participating coffeeshops supplied by designated growers. Enforcement against unregulated hashish was temporarily deferred until 1 September 2025. These are implementation milestones, not findings that health improved or organised crime declined. The experiment concerns participating municipalities and cannabis, not a nationwide cocaine or MDMA market.[14]

Regulating supply could improve traceability, product oversight and accountability while reducing participating shops' reliance on illegal suppliers. Whether this translates into less total offending requires evaluation outside the shops as well. Changes in neighbouring areas, consumer sourcing, product characteristics and health outcomes are relevant. A process working as intended is not yet proof of a favourable overall outcome.

The wider Dutch drug economy includes international trafficking and synthetic-drug production for foreign customers. The National Drug Monitor documents cross-border supply, synthetic-drug laboratories and waste dumping. Reforming domestic cannabis sales does not remove foreign demand for illicit drugs. Even wider domestic regulation would not automatically legalise exports or eliminate foreign criminal markets. No defensible percentage of all Dutch organised crime can be promised from cannabis reform alone.[15]

Plausible effects are not guaranteed outcomes
Policy changePlausible benefitWhat remains unresolved?
Less criminal punishment for possessionLess criminal-justice involvement and potentially fewer barriers to seeking help.Illegal production, product risk and the availability of care.
Controlled cannabis supplyMore accountable supply to participating shops and less reliance on illegal wholesalers.Residual markets, displacement, consumer response and long-term health effects.
Broader commercial availabilityPotentially more displacement of existing illicit retail sales.Incentives to increase sales, frequent use, dependence and the effectiveness of safeguards.

Regulating composition does not remove a drug's own toxicity. For example, the National Drug Monitor describes serious MDMA complications, including overheating and disturbances of salt balance, even without assuming an adulterated product. The case for testing or production standards must therefore be separated from a claim of harmlessness. This report provides no basis for recommending non-medical consumption.[17]

11. The strongest reasonable arguments on both sides

The strongest case for reform

Existing prohibition has costs as well as benefits. Supporters can reasonably argue that criminal punishment is a blunt response to personal use, and that leaving supply wholly to illegal businesses forfeits opportunities for oversight.

  • Reduce punishment and its social consequences, including unequal burdens on disadvantaged groups.
  • Make treatment easier to approach and direct resources towards serious harm.
  • Introduce product accountability and weaken part of the illegal market.
  • Evaluate less punitive options rather than assuming existing policy is the safest possible baseline.

The strongest case for caution

Removing prohibition does not remove the need to protect health. Critics can reasonably argue that increasing availability, normalisation and commercial incentives may create harms that are difficult to reverse.

  • Protect young people and those vulnerable to dependence or psychiatric problems.
  • Avoid an industry whose revenue depends on expanding frequent consumption.
  • Account for residual illegal sales, international trafficking and enforcement costs.
  • Require substance-specific evidence rather than extrapolating from cannabis or supervised treatment.

These arguments do not force a choice between unrestricted commerce and maximum punishment. A serious assessment compares concrete options, including maintaining current rules, and specifies goals before measuring results. Monitor health, victimisation, criminal-justice burdens, illegal-market activity and distributional effects separately. The evidence supports some narrower conclusions; it does not settle how society should weigh liberty, protection, fairness and risk, or justify a promised numerical reduction in violence.

12. What US alcohol prohibition and repeal actually teach us

The United States had national alcohol prohibition from 1920 to 1933. It restricted production and sale, rather than making all drinking itself a federal crime. Repeal ended national prohibition, not every state or local restriction. This was therefore neither a controlled experiment nor an overnight switch to an unregulated market.[24]

Did prohibition reduce drinking—and what happened after repeal?

It is misleading to say prohibition achieved nothing because people continued to drink. A historical reconstruction by Miron and Zwiebel used indicators including mortality, mental-health and crime statistics to estimate consumption. Its results are summarised below. These are one study's estimates from imperfect historical records, not precise direct measurements or an uncontested account of causation.[23]

Miron and Zwiebel's reconstruction, published in 1991; consumption relative to the pre-prohibition level
PeriodEstimated patternWhat this challenges
Initially under prohibitionAbout 30% of the earlier level.“A ban cannot reduce consumption.”
Later under prohibitionAbout 60–70% of the earlier level.“The initial reduction was fully sustained.”
Immediately after repealLittle difference from late prohibition.“Repeal immediately caused a huge jump in drinking.”
Over the following decadeA return to approximately the earlier level.“Legalisation permanently kept consumption at the reduced level.”

Historian Jack Blocker also concludes that prohibition lowered consumption and warns against the conventional story of complete failure. His review stresses the longer history of temperance measures and the Great Depression's role in changing political priorities. He describes a much longer return to the earlier consumption peak. That is not necessarily the same reference level as in the table: the sources do not establish a single uncontested timeline for a return to earlier consumption levels. This supports taking potential health benefits seriously, without treating any single consumption estimate as definitive.[24]

What happened to organised crime and violence?

Illegal alcohol provided business opportunities for organised crime. Legal supply could replace some of those transactions after repeal, but organised crime existed before national prohibition and persisted afterwards. That persistence does not establish that every lost alcohol sale was replaced by an equally profitable crime elsewhere. Nor does it establish that removing the illegal alcohol market had no benefit.[24]

Claims about total violence need more caution. In an analysis of state temperance laws and homicide, Emily Owens found no average increase in murder when alcohol markets were criminalised; her analysis attributed much of the wider historical trend to demographic changes. That challenges a simple causal story, but does not prove that illegal alcohol markets generated no violence.[25]

A further Owens study distinguishes market violence from violence associated with drinking: prohibition can increase the former while reducing the latter. Its analysis of age-specific homicide patterns supports considering those competing effects. Therefore, changes in total homicide cannot simply be equated with changes in bootlegging violence, and a fall after repeal would not by itself prove repeal caused it.[26]

The defensible historical lesson: prohibition can reduce consumption while creating illegal-market harms. Repeal can remove some criminal opportunities without eliminating organised crime or alcohol-related harm. Neither “bans never work” nor “legalisation solves crime” follows from this history.

Modern cocaine and MDMA markets differ from historical alcohol markets in products, use patterns, international supply and institutions. US history helps identify mechanisms and test simplistic claims; it cannot supply a reliable percentage for the effect of Dutch drug legalisation today.

13. Methods, source access and limitations

This is a sourced explanatory report, not a new systematic review or a complete legal inventory. Research was checked on 20 September 2026. Sources were selected for direct relevance: official statistics and policy descriptions, systematic reviews and original studies. Publication dates and observation periods are distinguished where figures are used. Older sources provide historical evidence, not measurements of the situation on the research date.

The Canadian expert review combines evidence with consultation and recommendations; it is not a controlled experiment. The Portuguese article is a critical legal and policy analysis, not a causal impact trial. The National Drug Monitor compiles official and research data and flags gaps in registration. The harm-ranking, Oregon assault, enforcement-violence and traffic-review findings below were checked against indexed abstracts; paywalled full texts were not independently assessed. Their limitations should not be hidden by the presence of a DOI.

The product comparison draws on official health and drug profiles, not a head-to-head trial. For US prohibition, the NBER abstract and Blocker's publicly available historical review were consulted. The Owens findings were checked against indexed abstracts, not the full papers. The historical figures are attributed estimates; they are not a pooled consensus or a prediction for present-day drug policy.

Numbers are included only where their definition and source could be verified. No estimate is offered for the percentage of Dutch violence that legalisation would prevent. Uncertainty about that figure is not proof of no benefit, nor permission to assume a large benefit.

  1. Scheim AI et al. Impact evaluations of drug decriminalisation and legal regulation on drug use, health and social harms: a systematic review. BMJ Open, 2020;10:e035148. Search through October 2018; full text accessed.
  2. World Health Organization. Alcohol. Official fact sheet; the mortality estimate cited here concerns 2019, not 2026.
  3. World Health Organization. Tobacco. Official fact sheet on health harms, regulation and illicit trade; accessed as a live page.
  4. Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. The Lancet, 2010. Expert scoring, not comparative clinical risk measurement. Verified abstract and metadata via Europe PMC.
  5. Rêgo X et al. 20 years of Portuguese drug policy — developments, challenges and the quest for human rights. Substance Abuse Treatment, Prevention, and Policy, 2021. Full-text historical policy analysis; not a current legal guide or causal trial.
  6. Health Canada. Canadian Cannabis Survey 2024: Summary. Official survey; usual source, spending and prevalence have different denominators. Self-report and recruitment limitations apply.
  7. Health Canada, independent expert panel. Legislative Review of the Cannabis Act: Final Report of the Expert Panel. 2024. Official review including the Statistics Canada spending estimate for the third quarter of 2023 and possession charges for 2017–2022.
  8. Lu R et al. The Cannabis Effect on Crime: Time-Series Analysis of Crime in Colorado and Washington State. Justice Quarterly, published online 2019. Original quasi-experimental analysis; full text accessed.
  9. Wu G, Willits DW. The Impact of Recreational Marijuana Legalization on Simple Assault in Oregon. Journal of Interpersonal Violence, published online 2022; data from 2007–2017. Verified abstract and metadata via Europe PMC; publisher full text not assessed.
  10. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database of Systematic Reviews, 2011;CD003410. Review summary and detailed abstract accessed; selected treatment-refractory populations, not retail legalisation.
  11. Statistics Netherlands (CBS). Safety Monitor 2023, chapter on traditional crime. Published 2024. Population victimisation survey; not a drug-policy evaluation.
  12. Werb D et al. Effect of drug law enforcement on drug market violence: a systematic review. International Journal of Drug Policy, 2011. Predominantly observational evidence. Verified abstract and metadata via Europe PMC.
  13. Government of the Netherlands. Gedoogbeleid softdrugs en coffeeshops. Official explanation of tolerated retail sale; read alongside the experiment-specific rules.
  14. Government of the Netherlands. Tijdlijn experiment gesloten coffeeshopketen. Official implementation timeline, including the experimental phase and hashish transition in 2025; no final impact evaluation is claimed.
  15. National Drug Monitor, Trimbos Institute and WODC. Handhaving en bestrijding: inbeslagnames en ontmantelingen. Institutional monitoring of Dutch trafficking and production; includes registration limitations and data covering different years.
  16. National Drug Monitor. Middelengebruik en geweld. Research synthesis and selected forensic registrations; explicitly notes the limited availability of recent Dutch research.
  17. National Drug Monitor. Ecstasy: ziekte en sterfte. Institutional synthesis of acute and longer-term health risks; not evidence that regulated retail access is safe.
  18. Dion PM et al. Road hazard: a systematic review of traffic injuries following recreational cannabis legalization. Canadian Journal of Emergency Medicine, 2024; search through October 2023. Verified abstract and metadata via Europe PMC; no pooled causal estimate.
  19. Dutch police. TERUGLEZEN: Dode bij schietincident Overasselt, twee agenten gewond. 1 September 2026. Primary source for the context; not evidence about motive, legal guilt or the effects of drug policy.
  20. US Food and Drug Administration. Nicotine Is Why Tobacco Products Are Addictive. Official explanation distinguishing nicotine dependence, smoke-related harms and medicinal nicotine replacement.
  21. European Union Drugs Agency. MDMA drug profile. Official pharmacological overview; distinguishes animal findings from uncertainty about effects in humans. Not a comparison of policy outcomes.
  22. European Union Drugs Agency. Cocaine drug profile. Official overview of pharmacology, dependence and differences between forms and routes of administration.
  23. Miron JA, Zwiebel J. Alcohol Consumption During Prohibition. NBER Working Paper 3675, 1991. Public abstract consulted; historical reconstruction using indirect indicators, not direct consumption measurement.
  24. Blocker JS Jr. Did Prohibition Really Work? Alcohol Prohibition as a Public Health Innovation. American Journal of Public Health, 2006. Public full-text historical review; interpretation of consumption, political context and organised crime.
  25. Owens EG. Are Underground Markets Really More Violent? Evidence from Early 20th Century America. American Law and Economics Review, 2011. Indexed abstract consulted through OpenAlex; full text not assessed. State-level temperance laws and homicide, not a direct estimate for today's drug markets.
  26. Owens EG. The American Temperance Movement and Market-Based Violence. American Law and Economics Review, 2014. Indexed abstract consulted through OpenAlex; full text not assessed. Distinguishes market violence from consumption-related violence using historical homicide patterns.